Skip to content

Prognostic value of soluble ST2 biomarker in Heart Failure patients

Prognostic value of soluble ST2 biomarker in Heart Failure patients with Reduced Ejection Fraction (HFrEF). - ST2HFrEF

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/01/005344
Enrollment
150
Registered
2015-01-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Heart failure with reduced ejection fraction

Interventions

None listed

Sponsors

Prof Dr CG Bahuleyan MDDM FRCP FSCAI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patients above 18 years of age. 2. Patients with at least one of the following clinical symptoms of HF a) dyspnea b) orthopnea c) paroxysmal nocturnal dyspnea d) increasing fatigue / worsening exercise tolerance AND at least two of the following physical signs of heart failure, a) edema (greater than 2 + lower extremity) b) pulmonary crackles greater than basilar c) jugular venous distension d) tachypnea (respiratory rate more than 20 breaths / minutes) e) rapid weight gain f) S3 gallop g) increasing abdominal distension or ascites h) hepatojugular reflux i) radiological evidence of worsening HF 3. Patients with EF 4. Willing to sign informed consent. 5. Expected to be available for follow-up visits.

Exclusion criteria

Exclusion criteria: 1. History of recent ( 2. Severe valvular heart disease. 3. History of recent ( 4. HF due to myocarditis 5. Patients with end stage renal failure (eGFR 6. Acute liver disease ( Alanine transaminase >= 2 times of the upper limit of normal) 7. Patients admitted with cardiogenic shock. 8. Patients with chronic obstructive pulmonary disease (COPD), Interstitial Lung Disease (ILD). 9. Patients undergoing chemotherapy. 10. Any medical condition substantially reducing life expectancy to

Design outcomes

Primary

MeasureTime frame
1. The Primary endpoints are a) Cardiac deaths occurring with in one year follow-up period b) Re-hospitalization for worsening of HF with in one year. 2. The secondary endpoints are a) All cause death with in one year. b) Change in LV function in one year. Timepoint: One year from recruitment

Secondary

MeasureTime frame
2. The secondary endpoints are a) All cause death with in one year. b) Change in LV function in one year. Timepoint: One year from recruitment

Countries

India

Contacts

Public ContactJinbert Lordson

Ananthapuri Hospitals and Research Institute

bahuleyan2001@yahoo.co.uk9447344882

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026